Toshiyuki Isoe

1.1k citations

30 papers · 935 indexed · h-index 16

Co-authors: T Tsuruo Tomoko Oh‐hara Satomi Tsukahara Y. Sugimoto Kazuo Kubo Kazuhide Nakamura Yoshiko Kobayashi Hideko Murooka
Topics: Angiogenesis and VEGF in Cancer (5 papers)Microbial Natural Products and Biosynthesis (4 papers)Ear and Head Tumors (4 papers)
Cited by: Toxicology Oncology Molecular Biology
Journals: Nature Communications Journal of Clinical Oncology Cancer Research
Partner nations: Japan Netherlands United States

In The Last Decade

Toshiyuki Isoe

29 papers receiving 908 citations

Peers

Countries citing papers authored by Toshiyuki Isoe

Since Specialization

Citations

This map shows the geographic impact of Toshiyuki Isoe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Toshiyuki Isoe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Toshiyuki Isoe more than expected).

Fields of papers citing papers by Toshiyuki Isoe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Toshiyuki Isoe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Toshiyuki Isoe. The network helps show where Toshiyuki Isoe may publish in the future.

Co-authorship network of co-authors of Toshiyuki Isoe

This figure shows the co-authorship network connecting the top 25 collaborators of Toshiyuki Isoe. A scholar is included among the top collaborators of Toshiyuki Isoe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Toshiyuki Isoe. Toshiyuki Isoe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Acellular, bioresorbable, ultra-purified alginate gel implantation for intervertebral disc herniation: Phase 1/2, open-label, non-randomized clinical trials 2025 ·Nature Communications ·Katsuhisa Yamada,Takahiko Hyakumachi,Terufumi Kokabu,(unknown),Toshiyuki Isoe,Khin Khin Tha,Yoichi M. Ito,Takashi Ohnishi,Tsutomu Endo,(unknown),Hiroyuki Tachi,Yuichiro Abe,Yoko Ishikawa,(unknown),Takashi Miyakoshi,Osamu Sugita,Norihiro Sato,Norimasa Iwasaki,Hideki Sudo	1
2	Multicenter phase II trial of trastuzumab and docetaxel for HER2-positive salivary gland cancer 2025 ·Japanese Journal of Clinical Oncology ·Satoshi Kano,(unknown),Ichiro Kinoshita,Yuichiro Tada,Kei Ijichi,Tomoko Yamazaki,Yasushi Shimizu,Yutaka Hatanaka,Hitoshi Tsuda,Shojiroh Morinaga,Yoshihiro Matsuno,Yoichi M. Ito,Naoki Nishimoto,Keiko Kobayashi,Toshiyuki Isoe,Takuro Noguchi,Akihiro Homma,Hirotoshi Dosaka‐Akita	1
3	Protocol for treating lumbar spinal canal stenosis with a combination of ultrapurified, allogenic bone marrow-derived mesenchymal stem cells and in situ-forming gel: a multicentre, prospective, double-blind randomised controlled trial 2023 ·BMJ Open ·Hideki Sudo,Takashi Miyakoshi,(unknown),Yoichi M. Ito,Kaoru Kahata,Khin Khin Tha,(unknown),(unknown),Tomoko Terada,Norimasa Iwasaki,Teruyo Arato,Norihiro Sato,Toshiyuki Isoe	1
4	Eribulin for patients with metastatic extramammary Paget disease: Study protocol for a single‐arm phase II trial 2023 ·Experimental Dermatology ·Takuya Maeda,Teruki Yanagi,Keiko Tokuchi,Takeru Funakoshi,(unknown),Toshiyuki Isoe,Yoichi M. Ito,Norihiro Sato,Hideyuki Ujiie	0
5	Status of the Current Treatment Options and Potential Future Targets in Uterine Leiomyosarcoma: A Review 2022 ·Cancers ·Hiroshi Asano,Toshiyuki Isoe,Yoichi M. Ito,Naoki Nishimoto,(unknown),(unknown),Hidemichi Watari	15
6	Exploratory clinical trial on the safety and capability of dMD-001 in lumbar disc herniation: Study protocol for a first-in-human pilot study 2021 ·Contemporary Clinical Trials Communications ·Katsuhisa Yamada,(unknown),Yoichi M. Ito,(unknown),Toshiyuki Isoe,(unknown),Osamu Sugita,Norihiro Sato,Khin Khin Tha,Norimasa Iwasaki,Teruyo Arato,Hideki Sudo	12
7	Abstract CT137: Phase II study of trastuzumab and docetaxel therapy in patients with HER2-positive recurrent and/or metastatic salivary gland carcinoma 2019 ·Cancer Research ·Ichiro Kinoshita,Satoshi Kano,Yasushi Shimizu,Naomi Kiyota,Yuichiro Tada,Kei Ijichi,(unknown),Akihiro Homma,Yoichi M. Ito,Kota Ono,Keiko Kobayashi,Toshiyuki Isoe,Yutaka Hatanaka,Hitoshi Tsuda,Shojiroh Morinaga,Yoshihiro Matsuno,Hirotoshi Dosaka‐Akita	7
8	Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors 2011 ·Clinical Cancer Research ·Ferry A.L.M. Eskens,Maja J.A. de Jonge,Pankaj Bhargava,Toshiyuki Isoe,Monette Cotreau,Brooke Esteves,Kunihiko Hayashi,Herman Burger,Maarten Thomeer,Leni van Doorn,Jaap Verweij	89
9	Anti‐tumor activity and tumor vessel normalization by the vascular endothelial growth factor receptor tyrosine kinase inhibitor KRN951 in a rat peritoneal disseminated tumor model 2008 ·Cancer Science ·Eri Taguchi,Kazuhide Nakamura,Toru Miura,Masabumi Shibuya,Toshiyuki Isoe	28
10	Abstract LB-201: Updated results from a Phase I study of AV-951 (KRN951), a potent and selective VEGFR-1, -2 and -3 tyrosine kinase inhibitor, in patients with advanced solid tumors 2008 ·Cancer Research ·Ferry A.L.M. Eskens,Maja J.A. de Jonge,Brooke Esteves,Monette Cotreau,Pankaj Bhargava,John L. Ryan,Leni van Doorn,Toshiyuki Isoe,Kunihiko Hayashi,Lena Ekman,Herman Burger,Jaap Verweij	14
11	Altered expression of topoisomerase IIα contributes to cross-resistant to etoposide K562/MX2 cell line by aberrant methylation 2005 ·British Journal of Cancer ·Takeshi Asano,Kazuhide Nakamura,Hisaki Fujii,Naoya Horichi,Tohru Ohmori,Kunihiro Hasegawa,Toshiyuki Isoe,Mitsuru Adachi,NOBORU OTAKE,Yoshitaka Fukunaga	18
12	Novel Potent Orally Active Selective VEGFR-2 Tyrosine Kinase Inhibitors: Synthesis, Structure−Activity Relationships, and Antitumor Activities of N-Phenyl-N‘-{4-(4-quinolyloxy)phenyl}ureas 2005 ·Journal of Medicinal Chemistry ·Kazuo Kubo,Toshiyuki Shimizu,(unknown),Hideko Murooka,(unknown),Kazuhide Nakamura,Kazumasa Hasegawa,Yoshiko Kobayashi,Noriko Takahashi,Kazumi Takahashi,Shinichiro Kato,Toshio Izawa,Toshiyuki Isoe	131
13	Synthesis and structure–activity relationship for new series of 4-Phenoxyquinoline derivatives as specific inhibitors of platelet-derived growth factor receptor tyrosine kinase 2003 ·Bioorganic & Medicinal Chemistry ·Kazuo Kubo,(unknown),Toshiyuki Shimizu,(unknown),Hideko Murooka,Tsuyoshi Nishitoba,Shinichiro Kato,Mikio Yagi,Yoshiko Kobayashi,(unknown),Toshiyuki Isoe,Kazuhide Nakamura,Hiroshi Iijima,Tatsushi Osawa,Toshio Izawa	19
14	Synthesis and structure-activity relationship of Quinazoline-Urea derivatives as novel orally active VEGF receptor tyrosine kinase selective inhibitors 2002 ·Kazuo Kubo,Yutaka Fujiwara,(unknown),Hideko Murooka,(unknown),Kazuhide Nakamura,Koki Hasegawa,Yoshiko Kobayashi,Naoko Takahashi,Kohei Takahashi,Masabumi Shibuya,(unknown),Toshiyuki Isoe	1
15	Gilvusmycin, a New Antitumor Antibiotic Related to CC-1065. 1999 ·The Journal of Antibiotics ·(unknown),Toshiyuki Isoe,Kazutoshi Shindo	11
16	Selective Inhibition of Platelet-Derived Growth Factor (PDGF) Receptor Autophosphorylation and PDGF-Mediated Cellular Events by a Quinoline Derivative 1997 ·Experimental Cell Research ·Mikio Yagi,Shinichiro Kato,Yoshiko Kobayashi,Kazuo Kubo,(unknown),Toshiyuki Shimizu,Tsuyoshi Nishitoba,Toshiyuki Isoe,Kazuhide Nakamura,(unknown),(unknown),(unknown),Tatsushi Osawa,Rie Onose,(unknown)	15
17	Antitumor activity of SPM VIII, a derivative of the nucleoside antibiotic spicamycin, against human tumor xenografts. 1994 ·The Journal of Antibiotics ·Masaru Kamishohara,Hiroyuki Kawai,(unknown),Toshiyuki Isoe,JUNICHIRO MOCHIZUKI,Takeshi Uchida,Yoichi Hayakawa,(unknown),Takashi Tsuruo,(unknown)	18
18	Structure-antitumor activity relationship of semi-synthetic spicamycin analogues. 1993 ·The Journal of Antibiotics ·Masaru Kamishohara,Hiroyuki Kawai,(unknown),Toshiyuki Isoe,JUNICHIRO MOCHIZUKI,Takeshi Uchida,Yoichi Hayakawa,Haruo Seto,Takashi Tsuruo,NOBORU OTAKE	30
19	Inhibition of different steps of the ubiquitin system by cisplatin and aclarubicin 1992 ·Biochimica et Biophysica Acta (BBA) - General Subjects ·Toshiyuki Isoe,Mikihiko Naito,Akio Shirai,Reiko Hirai,Takashi Tsuruo	18
20	Inhibition of ubiquitin-ATP-dependent proteolysis and ubiquitination by cisplatin. 1992 ·PubMed ·Toshiyuki Isoe,M. Naito,Reiko Hirai,T Tsuruo	12

About Toshiyuki Isoe

Toshiyuki Isoe is a scholar working on Toxicology, Oncology and Pharmacology, having authored 30 papers that have together received 935 indexed citations. Recurring topics across this work include Angiogenesis and VEGF in Cancer (5 papers), Microbial Natural Products and Biosynthesis (4 papers) and Ear and Head Tumors (4 papers). The work is most often cited by research in Toxicology (66 citations), Oncology (385 citations) and Molecular Biology (623 citations). Toshiyuki Isoe has collaborated with scholars based in Japan, Netherlands and United States. Frequent co-authors include T Tsuruo, Tomoko Oh‐hara, Satomi Tsukahara, Y. Sugimoto, Kazuo Kubo, Kazuhide Nakamura, Yoshiko Kobayashi, Hideko Murooka, Masabumi Shibuya and Kazumi Takahashi. Their work appears in journals such as Nature Communications, Journal of Clinical Oncology and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact